Literature DB >> 27695504

Vitamin D receptor gene FokI polymorphisms and tuberculosis susceptibility: a meta-analysis.

Yan Cao1, Xinjing Wang1, Zhihong Cao1, Xiaoxing Cheng1.   

Abstract

INTRODUCTION: The association between FokI polymorphism of vitamin D receptor (VDR) and tuberculosis (TB) susceptibility has been investigated previously; however, the results were inconsistent and conflicting. In the present study, a meta-analysis was performed to assess the relationship between VDR FokI gene polymorphism and the risk of TB.
MATERIAL AND METHODS: Databases including PubMed and Embase were searched for genetic association studies of FokI polymorphism of vitamin D receptor (VDR) and TB. Data were extracted by two independent authors and the pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to assess the strength of the association between VDR FokI gene polymorphism and TB risk. Meta-regression and subgroup analyses were performed to identify the source of heterogeneity.
RESULTS: Thirty-four studies with a total of 5669 cases and 6525 controls were reviewed in the present meta-analysis. A statistically significant correlation was found between VDR FokI gene polymorphism and increased TB risk in two comparison models: the homozygote model (ff vs. FF: OR = 1.37, 95% CI: 1.17-1.60; Pheterogeneity = 0.001) and the recessive model (ff vs. Ff + FF: OR = 1.32, 95% CI: 1.14-1.52; Pheterogeneity = 0.006). Meta-regression found no source contributing to heterogeneity. However, sub-group analyses revealed that there was a statistically increased TB risk in the East and Southeast Asian population.
CONCLUSIONS: Synthesis of the available studies suggests that homozygosity for the FokI polymorphism of the VDR gene might be associated with an increased TB risk, especially in the East and Southeast Asian population. Additional well-designed, larger-scale epidemiological studies among different ethnicities are needed.

Entities:  

Keywords:  FokI polymorphisms; tuberculosis susceptibility; vitamin D receptor

Year:  2016        PMID: 27695504      PMCID: PMC5016579          DOI: 10.5114/aoms.2016.60092

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


Introduction

Tuberculosis (TB) is one of the most important infectious diseases, with an estimated 9.0 million new cases and 1.5 million deaths worldwide in 2013, and more than half were in the South-East Asia and Western Pacific Regions [1]. It is suggested that the susceptibility to disease after infection with Mycobacterium tuberculosis is influenced by many risk factors, such as malnutrition, HIV infection, and environmental and host genetic factors [2-5]. Host genetic factors implicated in human susceptibility to TB include NRAMP, HLA-DQB1, interleukin (IL) genes and the vitamin D receptor (VDR) [6-8]. Vitamin D deficiency seems to be involved in susceptibility to TB and severity of the disease [9], and 1,25-dihydroxyvitamin D3, the activated form of vitamin D, is a potent immune modulator. Expression and nuclear activation of the VDR are essential for these activities of vitamin D. The VDR gene is located on the long arm of chromosome 12, and several polymorphisms occur in the 5′ regulatory region, coding region and 3′ untranslated region (UTR) [10]. Among all the gene loci, the one most studied recently is FokI [11-15], which can regulate the transcriptional activity of the gene [16]. FokI polymorphism in combination with low serum vitamin D3 may attenuate VDR functions, which in turn is strongly associated with TB [11]. Several studies have tried to investigate the role of FokI gene polymorphism on susceptibility to TB, but they have not reached a consensus. To date, two analyses on the FokI polymorphism and TB risk across different ethnicities have been reported [17, 18], but they failed to identify a significant association of FokI polymorphism in overall populations. In addition, more recent studies concerning the association between the polymorphism and TB risk in different populations have not included the two analyses [8, 12–15, 19–24]. Furthermore, several important factors which may bias the results were not clearly addressed, such as Hardy-Weinberg equilibrium (HWE). Thus, it is necessary to evaluate the true association of the VDR FokI gene polymorphism and the risk of TB. In the present study, we performed an updated meta-analysis to address these discrepancies and to explore the risk factors associated with TB.

Material and methods

Literature search strategy

We performed a literature search of the PubMed, Web of Science and Embase web databases with a combination of the key words ‘‘VDR’’ or “Vitamin D receptor”; “FokI”, “rs10735810”; “polymorphism” AND “Tuberculosis’’ up to January 2015. Furthermore, we evaluated potentially relevant genetic association studies by manual searching of references of relative articles and reviews. Search results were limited to human populations. No language restrictions were applied.

Inclusion and exclusion criteria

Published articles included in the current meta-analysis were selected according to the following criteria: (1) appraisal of the association between VDR FokI gene polymorphism and TB risk, (2) case-control study design, (3) with clearly described and confirmed TB patients and TB-free controls, (4) containing available genotype frequency in cases and controls. The major reasons for study exclusion were data overlapping, case-only studies, reviews, repeated literature, and without genotype frequencies.

Data extraction and quality assessment

Data of each retrieved publication were independently abstracted in duplicate by two independent investigators with a standard procedure. Data extracted from the retrieved publications included the name of the first author, publication year, the country of origin, ethnicity, source of controls, number of cases and controls, study type, diagnosis method of cases, the selection of controls and genotype frequencies. The Hardy-Weinberg equilibrium (HWE) was examined by χ2 test (p < 0.05 was considered as significant disequilibrium) based on FokI genotyping distribution in controls.

Statistical analysis

Data from the meta-analysis were analyzed using STATA software (Version 12.1; Stata Corp, College Station, Texas, USA). The significance of the association for five comparison models – allele model (f vs. F), homozygote model (ff vs. FF), heterozygote model (Ff vs. FF), dominant model (ff + Ff vs. FF) and recessive model (ff vs. Ff + FF) – was evaluated for 34 studies separately. All associations were evaluated by calculating odds ratios (ORs) with the 95% confidence interval (CI). The statistical heterogeneity between studies was checked using the χ2-based Q test and considered significant at p < 0.05. When there was no significant heterogeneity, the fixed effects model (Mantel-Haenszel method) was used; otherwise, the random-effects model (the DerSimonian and Laird method) was used. Sensitivity analyses were performed to identify an individual study's effect on pooled results and test the reliability of results. Meta-regression analysis was performed to explore the source of potential heterogeneity. Stratification analyses were performed to further identify the possible source of heterogeneity among variables, such as ethnicity and sample size (studies with more than 500 participants were defined as ‘‘large’’, and studies with less than 500 participants were defined as ‘‘small’’). Publication bias was assessed with both Egger's test and Begg's funnel plot, and the statistical significance was defined as p < 0.05. All p values were two-sided.

Results

Characteristics of enrolled studies

A flow chart of the study selection process is shown in Figure 1. According to the inclusion criteria, 34 qualified case-control studies were selected in the final analysis after the literature search from the PubMed (Medline), Web of Science and Embase web databases [8, 10–15, 19–45]. Twenty-four studies were based on Asian populations [8, 10–13, 19–37], seven were based on African populations [14, 15, 38–42] and the remaining three were conducted in Europe and America [43-45]. The eligible studies contained 4 “large” studies [19, 29, 40, 42] and 30 “small” studies [8, 10–15, 21–28, 30–39]. Thirty studies were genotyped by restriction fragment length polymorphism (RFLP) analysis and five were conducted by other methods [19, 23, 38, 40, 41]. The detailed characteristics of the enrolled studies are listed in Table I. A total of 5669 TB cases were obtained in the 34 studies, including 5126 (92.3%) with pulmonary TB and 426 (7.7%) with extra-pulmonary TB. The corresponding controls for the TB cases numbered 6525. Distribution of genotypes and HWE p-values in the controls are shown in Table II. Among the controls, the genotype distribution for 31 studies of the assessed polymorphisms was in HWE, except for 3 studies from India and Iran [31, 32, 35].
Figure 1

Flow diagram of search strategy and study selection process (TIF)

Table I

Main characteristics of included studies summarized for the meta-analysis

YearFirst authorCountryEthnicityStudy designTuberculosis Part of the bodySample size Cases/controlsDiagnosis methodGenotyping methodControls sourceHIV statusAge, genderDiabetes status
2014ArjiMoroccoArab or BerberPBPulmonary tuberculosis274/203AFB smear and culturePCR-RFLPHealthy personsNegativeMatchedNegative
2014MahmoudEgyptEgyptianPBPulmonary tuberculosis40/25AFB smear and culturePCR-RFLPHealthy personsNot availableMatchedNegative
2014SinagaIndonesianIndonesian BatakPBPulmonary tuberculosis76/76Clinical evaluation, AFB smear and chest radiographyPCR-RFLPHealthy health workers, tuberculin skin test positivity (61.7%)NegativeMatchedNegative
2013WuChinaChinese KazakhPBPulmonary tuberculosis213/211Clinical symptoms bacteriology X-rayPCR-RFLPHealthy personsNegativeMatchedNegative
2013JoshiIndiaIndianPBPulmonary tuberculosis110/225AFB smearPCR-RFLPHousehold contacts (110) and healthy persons (115)NegativeMatchedNegative
2012RathoredIndiaIndianPBMDR tuberculosis and drug-sensitive pulmonary tuberculosis692/205AFB smear and culturePCR-RFLPHealthy personsNegativeMatchedNegative
2011KimSouth KoreanKoreanPBPulmonary (98) and extra-pulmonary tuberculosis (62)160/156AFB smear and culturePyro sequencingHealthy personsNot availableMatchedNot available
2011KangSouth KoreanKoreanPBPulmonary tuberculosis103/105AFB smear and culturePCR-RFLPHealthy personsNot availableMatchedNot available
2011SinghIndiaIndo-Caucasian Brahmin casteHB, PBPulmonary tuberculosis101/225AFB smear or culturePCR-RFLPHealthy personsNegativeNot matchedNot available
2011SharmaIndiaIndianPBPulmonary tuberculosis474/607AFB smear or culturePCR-RFLPHealthy personsNot availableMatchedNot available
2011AtesTurkeyAnatolianPBPulmonary (98) and extra-pulmonary tuberculosis (30)128/80AFB smear or culturePCR-RFLPHealthy personsNot availableMatchedNot available
2010MarashianIranIranianHBPulmonary tuberculosis164/50AFB smear and X-rayPCR-RFLPContactsNot availableMatchedNot available
2010ZhangChinaChinese HanPBSpinal tuberculosis110/102Postoperative pathologyPCR-RFLPUnrelated contactsNegativeMatchedNegative
2009BanoeiIranIranianPBPulmonary tuberculosis60/62Confirmed in Massih DaneshvariPCR-RFLPHealthy subjectsNegativeMatchedNegative
2009MerzaIranIranianHBPulmonary tuberculosis117/60AFB smear and X-rayPCR-RFLPContactsNot availableMatchedNot available
2009VidyaraniIndiaDravidianPBPulmonary tuberculosis40/49AFB smear and culturePCR-RFLPNormal healthy subjectsNot availableMatchedNot available
2009SelvarajIndiaIndianHBPulmonary tuberculosis65/60Clinical symptom, AFB smear and culturePCR-RFLPHealthy subjectsNegativeMatchedNot available
2009AlagarasuIndiaDravidianHBPulmonary (187) and extra-pulmonary tuberculosis (30)217/144AFB smear, clinical criteria and X-rayPCR-RFLPHealthy controlsCases (51%), controls (0)MatchedNot available
2008SelvarajIndiaDravidianHBPulmonary tuberculosis51/60AFB smear and culturePCR-RFLPNormal healthy subjectsNegativeMatchedNot available
2008LiuChinaChinese HanPBPulmonary tuberculosis60/30AFB smear and cultureSNaPshotNormal healthy subjectsNegativeMatchedNegative
2007WilburParaguayAche, Chiripa, GuaranÍPBPulmonary tuberculosis54/124Clinical symptoms, PPD testPCR-RFLPNo symptomsNot availableNot availableNot available
2007OlesenGuinea-BissauPapel, Manjaco, Mancanha, Balanta, Fulani, Mandinka and othersPBPulmonary tuberculosis320/344AFB smear and clinical criteriaTaqManHealthy controlsHIV positive in 33% of cases and negative in controlsGender not matchedNot available
2007BabbSouth AfricaSouth AfricanHBPulmonary tuberculosis249/352AFB smear and X-rayPCR-RFLPNo clinical history or symptoms of TBNegativeNot availableNot available
2007SoborgTanzaniaTanzanianHBPulmonary tuberculosis435/416CulturePCR-SSPCulture negativeHIV positive in 44% of cases and 18% of controlsGender not matchedNot available
2006Chen XRChinaChinese TibetansPBPulmonary tuberculosis140/139Clinical symptoms, AFB smear and X-rayPCR-RFLPHousehold contactsNegativeMatchedNegative
2006LombardVendaVendaHBPulmonary and meningeal tuberculosis66/86AFB smearARMS-PCRHealthy controls with no history of TBNegativeNot availableNot available
2004BornmanGambia, Guinea-Bissau, GuineaGambia, Guinea-Bissau, GuineaHBPulmonary tuberculosis416/718AFB or culturePCR-RFLPHealthy community control subjectsCases (12.5%), controls (6.8%)MatchedNot available
2004Selvaraja IndiaIndianHBSpinal tuberculosis patients64/103X-ray and clinical criteriaPCR-RFLP77 were contacts and 26 were normal healthy subjectsNot availableMatchedNot available
2004Selvarajb IndiaIndianHBPulmonary tuberculosis46/64AFB smear, culture and radiographic abnormalitiesPCR-RFLPClinically normalNegativeMatchedNot available
2004RothPeruAmerindianPBPulmonary tuberculosis100/201AFB smearPCR-RFLPTwo healthy controls, 1 PPD + and 1 PPD–NegativeMatchedNot available
2004LiuChinaChinese HanPBPulmonary tuberculosis120/240AFB smear, culture and X-rayPCR-RFLPNormal controlsNegativeNot availableNegative
2004LiuChinaChinese HanPBPulmonary tuberculosis76/171Culture and X-rayPCR-RFLPNormal controlsNot availableMatchedNegative
2003SelvarajIndiaIndianHBPulmonary tuberculosis120/80CulturePCR-RFLPPatient contactsNot availableMatchedNot available
2000WilkinsonIndiaGujaratiHBPulmonary tuberculosis (27) and military tuberculosis (64)91/116Biopsy or culture TuberculosisPCR-RFLPContacts with no TBNegativeGender not matchedNot available

PB – population-based, HB – hospital-based, AFB – acid-fast bacilli, HIV – human immunodeficiency virus, MDR – multi-drug resistance for isoniazid and rifampicin, PPD – purified protein derivative, SNPs – single nucleotide polymorphism, TB – tuberculosis, PCR-RFLP – polymerase chain reaction–restriction fragment length polymorphism.

Table II

Distribution of gene polymorphism of studies included in the meta-analysis

YearFirst authorCaseControl
GenotypeMinor alleleGenotypeMinor alleleHWE
FFFfffMAFFFFfffMAFP-value
2014Arji151103200.2610982120.260.5038
2014Mahmoud122080.45101050.40.404
2014Sinaga274270.373034120.380.6497
2013Fang7296450.4410188220.310.6642
2013Joshi5146130.3311885220.290.252
2012Rathored319298750.321188070.230.1356
2011Kim4775380.474673370.470.4463
2011Kang3058150.434143210.400.1240
2011Singh554060.2696110190.330.1069
2011Sharma7767100.28395197360.210.0880
2011Ates5860100.31353780.330.6945
2010Marashian9757100.23153050.400.0771
2010Zhang1643510.662647290.510.4330
2009Banoei302190.33292760.310.9375
2009Merza674640.23352500.210.0415
2009Vidyarani231430.25202900.300.0033
2009Selvaraj332930.27332610.230.1019
2009Alagarasu13866130.21815940.230.0766
2008Selvaraj311640.24273300.280.0033
2008Liu1625190.53111720.350.1789
2007Wilbur351900.18814210.180.0740
2007Olesen198106160.22207118190.230.6862
2007Babb132104130.26203129200.240.9337
2007Soborg288128190.19267128210.200.2734
2006Chen6056240.37706090.280.4144
2006Lombard432120.19641820.130.5917
2004Bornman258138200.21444242320.210.8932
2004Selvaraj[a] 471520.15553990.280.5834
2004Selvaraj[b] 281530.23382330.230.8388
2004Roth932590.7514781090.740.9928
2004Liu2963280.5085120350.400.4821
2004Liu W2934130.399070110.270.5930
2003Selvaraj783660.20432980.280.3551
2000Wilkinson523180.26743930.190.4178

HWE – Hardy-Weinberg equilibrium, MAF – minor allele frequency

the different articles by the same author in the same year.

Flow diagram of search strategy and study selection process (TIF) Main characteristics of included studies summarized for the meta-analysis PB – population-based, HB – hospital-based, AFB – acid-fast bacilli, HIV – human immunodeficiency virus, MDR – multi-drug resistance for isoniazid and rifampicin, PPD – purified protein derivative, SNPs – single nucleotide polymorphism, TB – tuberculosis, PCR-RFLP – polymerase chain reaction–restriction fragment length polymorphism. Distribution of gene polymorphism of studies included in the meta-analysis HWE – Hardy-Weinberg equilibrium, MAF – minor allele frequency the different articles by the same author in the same year.

Sensitivity analyses and publication bias

In the sensitivity analysis, the influence of each individual data set on the pooled OR was assessed by deleting one single study each time. The results showed that the corresponding pooled ORs were not materially varied, suggesting stability of this meta-analysis (data not shown). Begg's funnel plot and Egger's test were used to evaluate the publication bias of the selected studies for the meta-analysis (Figure 2). Begg's funnel plot seemed symmetrical in all genetic models. Furthermore, the statistical results from Egger's test supported the result of Begg's funnel plot indicating that there was no publication bias among all genetic models (p > 0.05) (Table III).
Figure 2

Funnel plot analysis to detect publication bias in 34 eligible studies. A – Funnel plot analysis of homozygote model (ff vs. FF). Egger's test p = 0.567, Begg's test p = 0.423; B – Funnel plot analysis of recessive model (ff vs. Ff + FF). Egger's test p = 0.419, Begg's test p = 0.343; the circles represent the weight of individual study. log – logarithm, SE – standard error (TIF)

Table III

Statistics to test the publication bias and heterogeneity in the meta-analysis

ComparisonsBegg's regression analysisEgger's regression analysisHeterogeneity analysisModel used for the meta-analysis
P-value95% confidence intervalP-valueQ-valuePheterogeneityI2 (%)
f vs. F0.614(–1.133)–0.4040.34188.470.00062.7Random
ff vs. FF0.441(–0.327)–0.5740.58065.900.00149.9Random
Ff vs. FF0.313(–0.949)–0.2410.23466.350.00150.3Random
ff + Ff vs. FF0.459(–0.918)–0.4090.44079.440.00058.5Random
ff vs. Ff + FF0.495(–0.327)–0.6400.51457.010.00642.1Random
Funnel plot analysis to detect publication bias in 34 eligible studies. A – Funnel plot analysis of homozygote model (ff vs. FF). Egger's test p = 0.567, Begg's test p = 0.423; B – Funnel plot analysis of recessive model (ff vs. Ff + FF). Egger's test p = 0.419, Begg's test p = 0.343; the circles represent the weight of individual study. log – logarithm, SE – standard error (TIF) Statistics to test the publication bias and heterogeneity in the meta-analysis

Meta-analysis results

We pooled all 34 studies together for the assessment of the relationship between the VDR FokI polymorphism and the risk of TB. The pooled ORs from overall studies indicated a significantly increased risk of TB in the homozygote model (ff vs. FF: OR = 1.37, 95% CI: 1.17–1.60; Pheterogeneity = 0.001, Figure 3) and recessive model (ff vs. Ff + FF: OR = 1.32, 95% CI: 1.14–1.52; Pheterogeneity = 0.006, Figure 4). However, no significant association was found in the allele model (f vs. F: OR = 1.09, 95% CI: 0.97–1.21; Pheterogeneity = 0.000, Figure 5) and in the dominant model (ff + Ff vs. FF: OR = 1.08, 95% CI: 0.99–1.17; Pheterogeneity = 0.000, Figure 6). The heterozygote model (Ff vs. FF: OR = 1.03, 95% CI: 0.95–1.13; Pheterogeneity = 0.001, Figure 7) failed to show any association with the risk of TB. The strength of the association between VDR FokI gene polymorphism and TB risk is shown in Table IV.
Figure 3

Forest plot of homozygote model for overall comparison (ff vs. FF) (TIF)

Figure 4

Forest plot of recessive model for overall comparison (ff vs. Ff + FF) (TIF)

Figure 5

Forest plot of allele model for overall comparison (f vs. F) (TIF)

Figure 6

Forest plot of dominant model for overall comparison (ff + Ff vs. FF) (TIF)

Figure 7

Forest plot of heterozygote model for overall comparison (Ff vs. FF) (TIF)

Table IV

Meta-analysis results

Variablef vs. Fff vs. FFff vs. Ff + FFff vs. FFff + Ff vs. FF
NORPhORPhORPhORPhORPh
Total341.09 (0.97–1.21)0.0001.37 (1.17–1.60)*0.0011.32 (1.14–1.52)*0.0061.03 (0.95–1.13)0.0011.08 (0.99–1.17)0.000
Ethnicities:
 ES Asians91.42 (1.20–1.69)*0.0551.98 (1.53–2.56)*0.0121.64 (1.31–2.06)*0.0031.37 (1.13–1.65)0.8531.52 (1.27–1.82)*0.695
 SW Asians150.92 (0.75–1.13)0.0001.28 (0.95–1.74)0.0071.33 (1.00–1.78)*0.0450.91 (0.79–1.05)0.0000.97 (0.85–1.11)0.000
 Africans71.01 (0.91–1.12)0.7311.01 (0.75–1.35)0.9850.10 (0.75–1.32)0.9901.02 (0.89–1.17)0.5331.01 (0.88–1.15)0.525
 Americans21.05 (0.76–1.45)0.8210.84 (0.35–1.98)0.9551.20 (0.74–1.94)0.7750.88 (0.51–1.53)0.3990.92 (0.54–1.56)0.592
 Europeans10.92 (0.60–1.40)–.0.75 (0.27–2.09)0.76 (0.29–2.02)0.98 (0.54–1.76)0.94 (0.54–1.65)
Sample size:
 Largea41.09 (0.97–1.21)0.0031.34 (0.96–1.88)0.0221.26 (0.90–1.76)0.0481.15 (0.99–1.34)0.0231.18 (1.02–1.36)*0.000
 Smallb301.06 (0.94–1.20)0.0001.38 (1.15–1.64)*0.0021.33 (1.14–1.56)*0.0120.98 (0.89–1.09)0.0031.04 (0.94–1.14)0.006
Genotyping method:
 PCR-RFLP291.08 (0.95–1.22)0.0001.47 (1.23–1.75)*0.0011.39 (1.19–1.63)*0.0101.05 (0.95–1.15)0.0001.10 (1.00–1.20)*0.000
 Other methods51.07 (0.86–1.33)0.1141.02 (0.71–1.45)0.2351.03 (0.74–1.44)0.1960.99 (0.81–1.19)0.6420.99 (0.83–1.19)0.447
Source of controls:
 Contactsc100.97 (0.75–1.26)0.0001.24 (0.91–1.68)0.0021.33 (1.03–1.71)*0.0220.93 (0.78–1.11)0.0120.99 (0.83–1.17)0.001
 Healthyd241.13 (1.01–1.27)*0.0011.42 (1.18–1.70)*0.0191.31 (1.10–1.56)*0.0281.07 (0.97–1.17)0.0061.11 (1.01–1.21)*0.001

N – number of studies included, OR – odds ratio, Ph – p-value for heterogeneity

OR with statistical significance

studies with more than 500 participants

studies with less than 5000 participants

studies with controls from patient contacts

studies with controls from healthy persons

Forest plot of homozygote model for overall comparison (ff vs. FF) (TIF) Forest plot of recessive model for overall comparison (ff vs. Ff + FF) (TIF) Forest plot of allele model for overall comparison (f vs. F) (TIF) Forest plot of dominant model for overall comparison (ff + Ff vs. FF) (TIF) Forest plot of heterozygote model for overall comparison (Ff vs. FF) (TIF) Meta-analysis results N – number of studies included, OR – odds ratio, Ph – p-value for heterogeneity OR with statistical significance studies with more than 500 participants studies with less than 5000 participants studies with controls from patient contacts studies with controls from healthy persons To account for the sources of heterogeneity, we performed meta-regression by publication years, ethnicity, sample size, genotyping methods, as well as source of controls and type of TB. However, no significant source was found to substantially contribute to heterogeneity (Table V).
Table V

Meta-regression analysis results

Variablef vs. Fff vs. FFff vs. Ff + FFFf vs. FFff + Ff vs. FF
N95% CIP-value95% CIP-value95% CIP-value95% CIP-valueORP-value
Publication years34(–52.14)–23.050.44(–92.13)–90.560.99(–76.13)–88.010.88(–65.78)–36.310.56(–61.78)–35.210.58
Ethnicities34(–0.48)–0.400.86(–1.17)–0.960.85(–1.13)–0.900.82(–0.62)–0.600.98(–0.614)–0.560.92
Sample size34(–0.06)–0.191.08(–0.24)–0.460.52(–0.25)–0.450.56(–0.10)–0.220.44(–0.08)–0.2200.35
Genotyping method34(–0.15)–0.150.96(–0.38)–0.370.98(–0.33)–0.360.94(–0.21)–0.190.95(–0.19)–0.190.97
Source of controls34(–0.11)–0.150.76(–0.28)–0.370.78(–0.14)–0.390.36(–0.22)–0.150.74(–0.18)–0.170.95
Type of tuberculosis34(–0.21)–0.990.97(–0.45)–0.510.90(–0.40)–0.460.89(–0.32)–0.250.79(–0.29)–0.250.87
Meta-regression analysis results To further investigate the heterogeneity, we performed subgroup analyses (Table IV). To evaluate the possible effect of the geographical differences on the variability of overall estimates, we classified the studies conducted in Asia into two groups: East and Southeast Asia (China, Indonesian and South Korean) and South and West Asia (India and Iran). As a result, the enrolled studies were divided into five subgroups including Africans, East and Southeast Asians, South and West Asians, Americans and Europeans. As for ethnicities, an increased TB risk was found in the East and Southeast Asia population in five comparison models: allele model (f vs. F: OR = 1.42, 95% CI: 1.20–1.69; Pheterogeneity = 0.055), homozygote model (ff vs. FF: OR = 1.98, 95% CI:1.53–2.56; Pheterogeneity = 0.012), recessive model (ff vs. Ff + FF: OR = 1.64, 95% CI: 1.31–2.06; Pheterogeneity = 0.003), heterozygote model (Ff vs. FF: OR = 1.37, 95% CI: 1.13–1.65; Pheterogeneity = 0.853) and dominant model (ff + Ff vs. FF: OR = 1.52, 95% CI: 1.27–1.82; Pheterogeneity = 0.695). In South and West Asians, however, no significant association was found in the heterozygote model (ff vs. Ff + FF: OR = 1.33, 95% CI: 1.00–1.78; Pheterogeneity= 0.045). Further subgroup analyses were stratified by the source of the controls. Studies were divided into healthy persons-based and patient contacts-based studies, and importantly the association in healthy persons-based studies was reinforced in the allele model (f vs. F: OR = 1.13, 95% CI: 1.01–1.27; Pheterogeneity = 0.001), the homozygote model (ff vs. FF: OR = 1.42, 95% CI: 1.18–1.70; Pheterogeneity = 0.019) and the recessive model (ff vs. Ff + FF: OR = 1.31, 95% CI: 1.10–1.56; Pheterogeneity = 0.028), which conferred a significantly increased risk of TB, whereas this risk was reversed in patient contacts-based studies with no significance in each model (Table IV). In addition, when categorized by the sample size with a cutoff of 500 individuals, 30 out of 34 studies had sample sizes less than 500 and conferred an increased risk of TB for two comparison models: the homozygote model (ff vs. FF: OR = 1.38, 95% CI: 1.15–1.64; Pheterogeneity = 0.002) and the recessive model (ff vs. Ff + FF: OR = 1.33, 95% CI: 1.14–1.56; Pheterogeneity = 0.012). For the subgroup analysis by the genotyping methods, the homozygote model (ff vs. FF: OR = 1.47, 95% CI: 1.23–1.75; Pheterogeneity = 0.001), recessive genetic model (ff vs. Ff + FF: OR = 1.39, 95% CI: 1.19–1.63; Pheterogeneity = 0.010) and dominant model (ff + Ff vs. FF: OR = 1.10, 95% CI: 1.00–1.20; Pheterogeneity = 0.000) remained statistically significant in PCR-RFLP studies (Table IV).

Discussion

Tuberculosis is one of the leading causes of morbidity and mortality, and the VDR gene might be important in modulating host susceptibility to TB because of the potential roles of VDR in the immune response to TB. However, many studies generated conflicting association data concerning the association between VDR FokI gene polymorphism and the risk of TB. Our present meta-analysis, based on 34 eligible studies until January 2015, provides evidence to propose a consistent effect of VDR FokI polymorphism. We found that the f allele was associated with a significantly increased risk of TB in the homozygote model (ff vs. FF) and the recessive model (ff vs. Ff + FF), especially in the East and Southeast Asian population. However, an insignificant association was found in South and West Asians, Africans, Americans and Europeans for all comparison models. To a certain extent, this finding could reflect the existence of racial differences, suggesting that this polymorphism might have a multifunctional role in the pathogenesis of TB or interact with other genetic and environmental factors. Previous studies including the WHO TB report suggested that the yellow race was more susceptible to TB than the black and white race [1]. Additionally, it was reported that the f allele frequency was higher in Asians than Africans [17]. Thus, the finding of this meta-analysis might be attributed to the racial differences. There are some limitations to this systematic review. First, some individual information such as age, sex, HIV status and environmental factors could not be obtained, which makes the detailed sub-grouping analyses and interpretation of the results difficult. Second, considering that diabetes, hypertension and any other medical problem may affect vitamin D level, the confounding effect should be taken into account. VDR FokI polymorphisms have been suggested to be related to diabetes in Asians [46]. Diabetes status in the study population may therefore influence the association observed for VDR polymorphisms and TB incidence. Therefore, the stratification of diabetes status would further reveal the relationship between VDR gene SNPs and TB. However, diabetes status was not reported in two-thirds of the enrolled studies. Therefore, it was not possible to apply stratification according to diabetes status. Third, the small sample sizes in some subgroup analyses may not comprehensively represent the population. More studies are needed to confirm the association of FokI polymorphisms and TB risk, especially in different ethnic populations. Fourth, the different experimental designs and diagnostic standards make the analyses prone to bias. Fifth, included studies were restricted to those published in English or Chinese in our study, which might introduce potential bias into data analysis as well. Sixth, based on the data provided by the articles and our own calculations, significant deviations from HWE (p < 0.05) in controls were observed for three studies based on Asians [31, 32, 35]. Thus, their results should be interpreted with more caution. We therefore repeated the meta-analyses after exclusion of these studies. However, this exclusion did not materially affect the results (Table VI). Although genome-wide association studies (GWAS) are important for the discovery of genetic variations, we did not identify any published GWAS on this subject. In conclusion, the results from this meta-analysis demonstrate that VDR FokI polymorphism is associated with increased TB risk, especially in East and Southeast Asians, which supports the hypothesis that VDR might play an important role in the host defense against TB. However, due to the moderate strength of the associations, their values to be used for risk prediction should be considered cautiously, and future large scale case-control studies are required to validate these findings.
Table VI

Sensitivity analyses of study with controls not in HWE excluded

Study with controls not in HWE excludedSummarized odds ratio (95% CI)No. of included studiesI2 (%)P-value
f vs. F1.097 (0.978–1.229)3165.30.113
ff vs. FF1.323 (1.037–1.689)3152.30.025
ff vs. Ff + FF1.320 (1.083–1.608)3139.70.006
Ff vs. FF1.042 (0.917–1.185)3147.40.526
ff + Ff vs. FF1.085 (0.945–1.246)3158.80.246

CI – confidence interval.

Sensitivity analyses of study with controls not in HWE excluded CI – confidence interval.
  41 in total

1.  Association of FokI and PvuII polymorphisms with breast cancer staging and survival among Caucasian women: a prospective study.

Authors:  Anneza I Yiallourou; Emmanouel Ekonomou; Vassilios Tsamadias; Konstantinos Nastos; Konstantinos Karapanos; Ioannis Papaconstantinou; Theodosios Theodosopoulos; John Contis; Efstathios Papalambros; Dionysios Voros; John Psychogios
Journal:  J BUON       Date:  2014 Jul-Sep       Impact factor: 2.533

2.  Correlation between Vitamin D receptor gene FOKI and BSMI polymorphisms and the susceptibility to pulmonary tuberculosis in an Indonesian Batak-ethnic population.

Authors:  Bintang Y M Sinaga; Muhammad Amin; Yahwardiah Siregar; Sori M Sarumpaet
Journal:  Acta Med Indones       Date:  2014-10

3.  Association of HLA-DR, -DQ, and vitamin D receptor alleles and haplotypes with tuberculosis in the Venda of South Africa.

Authors:  Zane Lombard; Desiré-Lee Dalton; Philip A Venter; Robert C Williams; Liza Bornman
Journal:  Hum Immunol       Date:  2006-05-22       Impact factor: 2.850

Review 4.  Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis.

Authors:  L Gao; Y Tao; L Zhang; Q Jin
Journal:  Int J Tuberc Lung Dis       Date:  2010-01       Impact factor: 2.373

5.  Serum vitamin D levels and VDR polymorphisms (BsmI and FokI) in patients and their household contacts susceptible to tuberculosis.

Authors:  L Joshi; M Ponnana; S R Penmetsa; P Nallari; V Valluri; S Gaddam
Journal:  Scand J Immunol       Date:  2014-02       Impact factor: 3.487

6.  Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis.

Authors:  P Selvaraj; S Prabhu Anand; M Harishankar; K Alagarasu
Journal:  J Clin Immunol       Date:  2009-02-14       Impact factor: 8.317

7.  Regulatory role of vitamin D receptor gene variants of Bsm I, Apa I, Taq I, and Fok I polymorphisms on macrophage phagocytosis and lymphoproliferative response to mycobacterium tuberculosis antigen in pulmonary tuberculosis.

Authors:  P Selvaraj; G Chandra; M S Jawahar; M Vidya Rani; D Nisha Rajeshwari; P R Narayanan
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

8.  Regulatory role of promoter and 3' UTR variants of vitamin D receptor gene on cytokine response in pulmonary tuberculosis.

Authors:  P Selvaraj; M Vidyarani; K Alagarasu; S Prabhu Anand; P R Narayanan
Journal:  J Clin Immunol       Date:  2008-01-30       Impact factor: 8.317

9.  [A case-control study on the vitamin D receptor gene polymorphisms and susceptibility to pulmonary tuberculosis].

Authors:  Wei Liu; Cui-ying Zhang; Xiao-ming Wu; Lei Tian; Chun-zhi Li; Qiu-min Zhao; Pan-he Zhang; Shu-mei Yang; Hong Yang; Xi-tan Zhang; Wu-chun Cao
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2003-05

10.  NRAMP1, VDR, HLA-DRB1, and HLA-DQB1 gene polymorphisms in susceptibility to tuberculosis among the Chinese Kazakh population: a case-control study.

Authors:  Fang Wu; Wanjiang Zhang; Le Zhang; Jiangdong Wu; Chunzhu Li; Xianjie Meng; Xi Wang; Peng He; Jie Zhang
Journal:  Biomed Res Int       Date:  2013-09-01       Impact factor: 3.411

View more
  9 in total

1.  Meta-Analysis of the Association Between the rs228570 Vitamin D Receptor Gene Polymorphism and Arterial Hypertension Risk.

Authors:  Ivone F O C Nunes; Ana A C M Cavalcante; Marcus V O B Alencar; Marcos D F Carvalho; José L R Sarmento; Nayra S C C A Teixeira; Adriana A Paiva; Lídia R Carvalho; Leopoldo F M Nascimento; Maria S P Cruz; Marcelo M Rogero; Andréia C B Lima; Cecilia M R G Carvalho
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

Review 2.  Mycobacterium tuberculosis and macrophage nuclear receptors: What we do and don't know.

Authors:  Chrissy M Leopold Wager; Eusondia Arnett; Larry S Schlesinger
Journal:  Tuberculosis (Edinb)       Date:  2019-04-25       Impact factor: 3.131

Review 3.  Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes.

Authors:  Prince N Dlozi; Angelina Gladchuk; Rustin D Crutchley; Nicole Keuler; Renier Coetzee; Admire Dube
Journal:  Biomed Pharmacother       Date:  2022-05-28       Impact factor: 7.419

4.  Vitamin D3 receptor polymorphisms regulate T cells and T cell-dependent inflammatory diseases.

Authors:  Gonzalo Fernandez Lahore; Bruno Raposo; Marie Lagerquist; Claes Ohlsson; Pierre Sabatier; Bingze Xu; Mike Aoun; Jaime James; Xiaojie Cai; Roman A Zubarev; Kutty Selva Nandakumar; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-21       Impact factor: 11.205

5.  FokI vitamin D receptor gene polymorphism and serum 25-hydroxyvitamin D in patients with cardiovascular risk.

Authors:  Sahar Nakhl; Ghassan Sleilaty; Eliane Chouery; Nabiha Salem; Ramez Chahine; Nassim Farès
Journal:  Arch Med Sci Atheroscler Dis       Date:  2019-12-31

6.  Risk of tuberculosis in low birth weight children from East Romania.

Authors:  Elena Ariela Banu; Aurel Nechita; Eva Maria Elkan-Cojocaru; Ginel Baciu; Alina Manole; Liliana Chelaru
Journal:  Arch Med Sci       Date:  2018-10-08       Impact factor: 3.318

7.  Vitamin D receptor gene polymorphisms and uterine fibroid incidence in Caucasian women.

Authors:  Michał Ciebiera; Małgorzata Wrzosek; Cezary Wojtyła; Kornelia Zaręba; Grazyna Nowicka; Grzegorz Jakiel; Marta Włodarczyk
Journal:  Arch Med Sci       Date:  2019-01-30       Impact factor: 3.318

8.  Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk.

Authors:  Cunzhong Yuan; Xiaoyan Liu; Rongrong Li; Shi Yan; Beihua Kong
Journal:  Arch Med Sci       Date:  2020-04-25       Impact factor: 3.318

Review 9.  Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility.

Authors:  Murugesan Harishankar; Paramasivam Selvaraj; Ramalingam Bethunaickan
Journal:  Front Med (Lausanne)       Date:  2018-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.